Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse.
Affiliation
Department of Endocrinology, Beaumont Hospital, Dublin, Ireland., diarmuidsmith@beaumont.ieIssue Date
2012-02-01T10:01:21ZMeSH
AgedDiabetes Mellitus, Type 2/chemically induced/complications/*physiopathology
Diabetic Angiopathies/chemically induced/etiology/*physiopathology
Female
Humans
Hypoglycemia/chemically induced/complications/*physiopathology
Myocardial Infarction/chemically induced/etiology/*physiopathology
Sulfonylurea Compounds/administration & dosage/*adverse effects
Treatment Outcome
Metadata
Show full item recordCitation
Diabet Med. 2011 Jul;28(7):876-9. doi: 10.1111/j.1464-5491.2010.03226.x.Journal
Diabetic medicine : a journal of the British Diabetic AssociationDOI
10.1111/j.1464-5491.2010.03226.xPubMed ID
21204965Abstract
BACKGROUND: Recent large-scale randomized trials of intensive therapy in Type 2 diabetes have reported increased cardiovascular morbidity and mortality in patient populations who experience a high frequency of hypoglycaemic events. However, there are few descriptions of hypoglycaemia leading directly to a myocardial infarction (MI) in the medical literature to date. CASE REPORT: In this article we describe the case of a 76-year-old woman without diabetes who presented with symptoms, left bundle branch block and raised troponin, indicative of an MI. She was also noted to be hypoglycaemic with a plasma glucose level of 2.5 mmol/l. It was subsequently discovered that she had mistakenly been dispensed glibenclamide, a long-acting sulphonylurea, in the preceding weeks. Her cardiac symptoms resolved completely upon treatment of her hypoglycaemia and she had no significant coronary artery disease on angiography. CONCLUSION: This is the first case of sulphonylurea-induced MI in a patient without diabetes and illustrates the adverse effects of acute hypoglycaemia upon the cardiovascular system.Language
engISSN
1464-5491 (Electronic)0742-3071 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1111/j.1464-5491.2010.03226.x
Scopus Count
Collections
Related articles
- Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
- Authors: Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D
- Issue date: 2008 Jun
- Cardiovascular safety of sulphonylurea: comment on the study by Monami et al.
- Authors: Du L, Chen Y, Shen J, Peng Y, Sun X
- Issue date: 2014 Jul
- Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
- Authors: Juurlink DN, Gomes T, Shah BR, Mamdani MM
- Issue date: 2012 Dec
- Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
- Authors: Sillars B, Davis WA, Hirsch IB, Davis TM
- Issue date: 2010 Sep
- Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.
- Authors: Monami M, Genovese S, Mannucci E
- Issue date: 2013 Oct